Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.

[1]  E. Biganzoli,et al.  Thrombospondin-1 and -2 in Node-Negative Breast Cancer: Correlation with Angiogenic Factors, p53, Cathepsin D, Hormone Receptors and Prognosis , 2000, Oncology.

[2]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[3]  A. Blann,et al.  Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. , 2000, Journal of the National Cancer Institute.

[4]  R. Price,et al.  Evidence for novel non-angiogenic pathway in breast-cancer metastasis , 2000, The Lancet.

[5]  S. Ran,et al.  Tumor infarction by targeting tissue factor to tumor vasculature. , 2000, Cancer journal.

[6]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[7]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Anthony J. Guidi,et al.  Association of angiogenesis in lymph node metastases with outcome of breast cancer. , 2000, Journal of the National Cancer Institute.

[9]  S. Fox,et al.  Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39 , 2000, British Journal of Cancer.

[10]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[11]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[12]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[13]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[14]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[15]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[16]  T. Powles,et al.  Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma , 1999, Cancer.

[17]  G. Yancopoulos,et al.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.

[18]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[19]  Hiroshi Takahashi,et al.  Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon , 1999, Nature Medicine.

[20]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[21]  H. Saji,et al.  Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[23]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[24]  B Vojnovic,et al.  Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. , 1999, Cancer research.

[25]  D. Massi,et al.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.

[26]  A. Tarkkanen,et al.  Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. , 1999, Journal of the National Cancer Institute.

[27]  J. Folkman,et al.  Involvement of platelets in tumour angiogenesis? , 1998, The Lancet.

[28]  E Biganzoli,et al.  Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. Bicknell,et al.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. , 1998, The Biochemical journal.

[30]  J. Isner,et al.  Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-specific Receptor Tyrosine Kinase Tie2* , 1998, The Journal of Biological Chemistry.

[31]  R. Nicosia.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? , 1998, The American journal of pathology.

[32]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[33]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[34]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[36]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[37]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[38]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[39]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[40]  Ulf Eriksson,et al.  Vascular endothelial growth factors VEGF‐B and VEGF‐C , 1997, Journal of cellular physiology.

[41]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Fox,et al.  Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. , 1997, Journal of the National Cancer Institute.

[44]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[45]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[46]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[47]  D. Hanahan,et al.  Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.

[48]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[49]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[50]  A. Giaccia,et al.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.

[51]  D. Senger.  Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. , 1996, The American journal of pathology.

[52]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[53]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[54]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[55]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[56]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[57]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[58]  B. Teicher,et al.  Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.

[59]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[60]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[61]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[62]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[63]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[64]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[65]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[66]  S. Brem,et al.  Angiogenesis as a marker of preneoplastic lesions of the human breast , 1978, Cancer.

[67]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.